Published By LIBRARY & INFORMATION CENTRE INDIAN...

Published By

LIBRARY & INFORMATION CENTRE

INDIAN PHARMACOPOEIA COMMISSION Ministry of Health & F. W., Govt. of India

Ghaziabad (U. P.)

Vol. 2, Issue 12, December 2017

2

Index Contents Page No.

Vol. 2, Issue 12, December 2017

Railway stations and petrol pumps to have generic store all over India

Dainik Jagran 5

India and the future of life sciences innovation

Mint 5

Drug makers pare costs as profitability continues to fall

Mint 7

Seasonal disease, doc strikes leave healthcare in a shambles

Hindustan times 8

Vaccine drive immune to stir

Hindustan times 8

Unlicensed body building supplements may face ban

Hindustan times 9

Who trolled for stand on gaming disorder?

The Times of India 10

Drugs consumables 30-35% of hosp bills, doc fees 10-20%


Cancer drug price hiked 15 fold in four years


Sun pharma’s US eye drug filing reason to cheer but cautiously

Mint 13

Encephalitis becoming a national problem, says report

Hindustan times 14

Bharti AXA launches smart super health policy

Hindustan times 14

Birth control for problem animals: which drug how to administer it

The Indian Express 15

Lupin drags govt to court over double taxation fear

The Economic Times 16

Sun rises 7% after USFDA nod to dry eye drug


Despite storage India discards 1m blood unit per year


3

3-Day pharma meet begins tomorrow

Hindustan times 19

Pharma cong urges centre to end dual control

Hindustan times 20

Aurobindo’d antibiotic API substandard: Maha FDA


Pharma marketing practices code soon

Mint 22

Blockchain pumping new life into old school cos like IBM


Drugmaker ignored over 200 Bad quality test says FDA


Big Pharma desperate for deals agnostic of geographies


Centre to verify claims of states via user feedback


Bringing down the cost of healthcare


37 drugs found sub standard

Dainik Jagran 27

Antibiotic over use is a silent killer


IISc: HIV drug elvitegravir lower the efficiency of immune system

The Hindu 29

NCCS’ novel approach improves success rate of bone marrow transplantation

The Hindu 30

IMA tightens the screws on antibiotic prescription

The Hindu 31

Healthcare beyond half the world’s reach, says WHO study


Daily Intake of hot tea decrease Glaucoma

Dainik Jagran 33

New health commission get green signal

Dainik Jagran 33

Medical Commission draft ready: Editorial

Dainik Jagran 34

4

Garlic can prevent tumour

Dainik Jagran 35

Ayurvedic dispensary to be shifted soon

Dainik Jagran 36

New Immunotherapy to foght cancer

Dainik Jagran 37

NPPA eases norms for new drug approvals

Mint 38

Regulator fortis kept profit margin as high as 1,737%


Drug controller allows indian firm to conduct phase 1 trial for zika vaccine


Aurobindo, DRL lead race to buy orchid


Pharma cos concerned over double Taxation on old stock of medicines


Indian drug makers may see a sharp rise in FDA inspections


NPPA notifies prices of 65 essential formulations


Indian drug makers may see a sharp rise in inspection


Twitter begins enforcing rules on hateful, abusive content


AIIMS GH to consider rotation of dept head


With UP as Lab WHO designs a list for safer childbirth


Beware price controls on medicine: it will deter pharma industry


5

Dated: 29-Dec-2017-Page-2


India and the future of life sciences innovation KURT STOECKLI, 29 Dec 2017 ZoomBookmarkSharePrintListenTranslate

India is known for many wonderful things. On the international stage, it is recognized as the

fastest-growing economy in the world, and is well-known for its culture, exquisite cuisine and sense of community and family, among many other qualities. One thing it is less known for is the discovery and development of new medicines. I think this will soon change. The Indian pharmaceutical industry is a world leader in bringing generic drugs to the market in a cost-effective way. Additionally, many Western pharmaceutical companies have established small molecule development and manufacturing in India. More recently, Indian pharma companies

have demonstrated the capability to develop biosimilars for global healthcare markets. These activities are highly valuable, providing essential and established medicines at more affordable prices to people around the world.

http://epaper.livemint.com/epaper/showarticle.aspx?article=77f05acd-727e-4163-a514-73aa7b9e48d1&key=52tf5I4paXaEMy4Q5%2fpanw%3d%3d&issue=67862017122900000000001001

http://epaper.livemint.com/epaper/showarticle.aspx?article=77f05acd-727e-4163-a514-73aa7b9e48d1&key=52tf5I4paXaEMy4Q5%2fpanw%3d%3d&issue=67862017122900000000001001

6

However, having worked for decades in multinational research and development of

new drugs, I think that the future of India will go beyond generics and biosimilars. There are

many attractive features that the existing Indian ecosystem can offer the life sciences industry

and I believe that India will eventually play a critical role in the advancement of innovative medicines. Improvements in genome sequencing have led to a better understanding of what causes and drives the progression of disease. Therapies based on translational strategies rationally target the mechanisms underlying the disease. Precision medicine combines both these ideals, by getting the right drug to the right patient at the right time. It is here that I see opportunities for globally operating Indian pharmaceutical companies to address unmet medical needs worldwide.

Companies that are based in India but have substantial US operations are perfect examples

of such innovators. Such companies are discovering new, cutting-edge precision medicines using state-of-the-art technologies, and hastening exploratory clinical studies in collaboration with major medical centres in India that provide unique access to treatment-naive patients. Public-private partnerships are further unlocking the potential of Indian biomedical research and

development. And people are taking notice. The environment for highly innovative and cost-effective biomedical research has changed markedly. Today, there is much more time and cost pressure on the research and development of innovative medicines, particularly with regard to preclinical and early clinical research.

Big Western pharma is facing challenges in this regard. While the industry has the capacity

and capability to develop drugs and commercialize them, and the economies of scale to do so

profitably, these organizations often lack the agility and flexibility to innovate constantly in the increasingly competitive realm of life sciences discovery. Many of the largest pharmaceutical companies in the world are relying on early-stage collaboration with start-up biotech firms and established academic labs to manage the inherently risky prospect of drug innovation. This type of early innovation will always be high-risk, but more importantly, will face progressive challenges of managing that risk in a nimble way. Essentially, it’s about finding methods and processes that accelerate success and help unsuccessful projects “fail faster”. The key to nimble

risk management will flow from innovation hypotheses grounded in translational medicine, patient stratification and value propositions that convince investors, payers and regulators of the potential improvement and superiority in standards of care.

Sixty years ago, the total number of physicians in India was less than 50,000; today there

has been a 16-fold increase to nearly 800,000 registered medical practitioners. Public health

centres, the foundation of rural healthcare in the country, have increased from less than 100 to

more than 23,000. This explosive growth is fertile ground for thought leaders, investors, regulators and medical centres to collaborate on developing the capabilities to nurture the type of start-up environment that will focus on innovation and better ways of healthcare delivery, with an eye on long-run rather than short-term profitability.

To capitalize on these opportunities, I think there are a number of steps that India can

take. For example, incentives for start-up biotech firms, and commitment to rigorous global compliance standards that help increase trust in the Indian life sciences industry. These trends are under way globally, but, in some respects, have yet to be initiated by experts with roots in India. Thought leaders must embrace a mindset that celebrates risk-taking and shows unwavering commitment to long-term objectives. By making investments in risky but nonetheless highly valuable emerging science, the global life sciences landscape will undergo an evolution as India transforms itself into a centre of excellence.

We have seen monumental progress in science and technology in recent years, most

notably in the field of immuno-oncology for some of the hardest-to-treat cancers. These innovations didn’t happen in isolation, but emerged from collaborative networks. Today,

innovation occurs in a global village, not in a single country. With so much to offer the life sciences, India is poised to become a dominant player. The potential for this groundswell to

materialize is happening today. It’s exciting to be a part of it. Kurt Stoeckli is president and chief scientific officer at Glenmark Pharmaceuticals.

7


8


9


10


11


12


13


14


15


16


17


18


19

(Chandigarh)


20


21


22


23



24


25


26


27


28


29


30


31


32


33



34


35


36

Dated: 14-Dec-2017-Page-II (Ghaziabad)

37


38


39


40


41


42


43


44


45


46


47

Dated: -Dec-2017-Page

48

Dated: 21-Dec-2017-Page19

49

Dated: 16-Dec-2017-Page22

*******************************************

Published By LIBRARY & INFORMATION CENTRE INDIAN...

Documents

Transcript of Published By LIBRARY & INFORMATION CENTRE INDIAN...